|
Protara Therapeutics, Inc. (Tara) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Protara Therapeutics, Inc. (TARA) Bundle
Vereinfachen Sie die Bewertung von Protara Therapeutics, Inc. (TARA) mit diesem anpassbaren DCF -Taschenrechner! Mit Real Protara Therapeutics, Inc. (TARA) -Fonds und einstellbaren Prognoseeingaben können Sie Szenarien testen und Protara Therapeutics, Inc. (TARA) in Minuten aufdecken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -7.8 | -33.8 | -46.1 | -64.6 | -43.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .2 | 1.2 | .2 | .3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -7.8 | -34.0 | -47.3 | -64.8 | -43.6 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 6.2 | 168.6 | 91.2 | 84.4 | 65.6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .5 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | 1.2 | 1.2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .7 | .9 | 1.0 | 1.6 | 2.4 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.9 | -.6 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -7.7 | -33.5 | -47.1 | -63.7 | -43.6 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7.0 | -34.0 | -47.7 | -63.4 | -41.1 | -2.2 | .0 | .0 | .0 | .0 |
| WACC, % | 10.82 | 10.83 | 10.83 | 10.82 | 10.83 | 10.83 | 10.83 | 10.83 | 10.83 | 10.83 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -34 | |||||||||
| Equity Value | 32 | |||||||||
| Diluted Shares Outstanding, MM | 11 | |||||||||
| Equity Value Per Share | 2.84 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Protara Therapeutics, Inc. (TARA) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template automatically computes Net Present Value (NPV) and intrinsic value for your convenience.
- Customizable and Professional: A refined Excel model that adjusts to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life TARA Financials: Pre-filled historical and projected data for Protara Therapeutics, Inc. (TARA).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Protara’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Protara’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Model: Download and open the Excel file featuring Protara Therapeutics, Inc. (TARA) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth projections, WACC, and capital investments.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to assess diverse valuation possibilities.
- 5. Make Informed Decisions: Deliver expert valuation insights to enhance your strategic choices.
Why Choose This Calculator?
- User-Friendly Interface: Perfect for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters to suit your financial analysis needs.
- Real-Time Valuation: Monitor immediate changes to Protara Therapeutics' valuation as you tweak inputs.
- Preloaded Data: Comes with Protara Therapeutics' actual financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Pharmaceutical Students: Understand drug development processes and analyze real-world case studies.
- Researchers: Utilize advanced models in your studies on biotechnology and therapeutics.
- Healthcare Investors: Evaluate your investment strategies and assess valuation metrics for Protara Therapeutics, Inc. (TARA).
- Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
- Entrepreneurs: Discover how public biotech firms like Protara Therapeutics, Inc. (TARA) approach market challenges.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Protara Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Protara Therapeutics, Inc. (TARA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.